Kamada Plans Three More Biosimilar Launches In Israel
Post Approval, Company Expects Sales Of $5m-$7m From The Candidates
Executive Summary
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.
You may also be interested in...
Kamada Licenses Alvotech Biosimilars In Israel
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Billionaire Mark Cuban Surprises With US Generics Venture
To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022.
Teva And Hikma Plan Long-Term Environmental Commitments
Teva has disclosed plans to focus on climate action and resilience, responsible use of natural resources and emissions, effluents and waste, as part of a long-term environmental sustainability commitment. Meanwhile, Hikma has at the same time committed “to further reducing our climate impact and improving the resilience of our business in the face of future climate change.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: